Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Total Return Calculator with Dividends Reinvested

Contineum Therapeutics, Inc. Class A Common Stock

Popular:

The total return for Contineum Therapeutics, Inc. Class A Common Stock (CTNM) stock is +159.52% over the past 12 months. So far it's up 4.13% this year. The 5-year total return is -22.99%, meaning $10,000 invested in CTNM stock 5 years ago would be worth $7,701 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in CTNM 1 year ago, it would be worth $25,616 today — you'd have gained $15,616.

With Dividends Reinvested$25,616+156.16%

Price Only (No DRIP)$25,616+156.16%

Period2025-06-12 → 2026-06-11

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in CTNM

1Y$25,952+$15,952 (+159.5%)159.5% CAGR

3Y$7,701-$2,299 (-23.0%)-8.3% CAGR

5Y$7,701-$2,299 (-23.0%)-5.1% CAGR

10Y$7,701-$2,299 (-23.0%)-2.6% CAGR

15Y$7,701-$2,299 (-23.0%)-1.7% CAGR

20Y$7,701-$2,299 (-23.0%)-1.3% CAGR

30Y$7,701-$2,299 (-23.0%)-0.9% CAGR

Contineum Therapeutics, Inc. Class A Common Stock did not pay dividends during this period. Total return = price return.

Loading CTNM total return...

As of 2026-06-12

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+4.13%	—	+4.13%	—	$10,413
1Y	+159.52%	159.52%	+159.52%	—	$25,952
3Y	-22.99%	-8.34%	-22.99%	—	$7,701
5Y	-22.99%	-5.09%	-22.99%	—	$7,701
10Y	-22.99%	-2.58%	-22.99%	—	$7,701
15Y	-22.99%	-1.73%	-22.99%	—	$7,701
20Y	-22.99%	-1.30%	-22.99%	—	$7,701
30Y	-22.99%	-0.87%	-22.99%	—	$7,701

Risk & Highlights

Best Year-4.87%2024

Worst Year-21.06%2025

Max Drawdown-29.84%2025-12-11 → 2026-01-08 · Recovered 2026-01-27

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+34.68%	+34.68%	—	+0.41%	+34.3pp
2025	-21.06%	-21.06%	—	+16.64%	-37.7pp
2024	-4.87%	-4.87%	—	+24.00%	-28.9pp

CTNM outperformed the S&P 500 by 136.84pp over the past year (+159.52% vs +22.68%).

Loading summary...

CTNM Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
CTNMContineum Therapeutics, Inc. Class A Common Stock	$443M	-13.1%	+4.1%	+159.5%	—	-23.0%	-23.0%	-23.0%
IMVTImmunovant, Inc.	$6.8B	+13.1%	+26.9%	+103.6%	—	+51.6%	+207.0%	+230.5%
PRTAProthena Corporation plc	$432M	-14.6%	-10.2%	+62.0%	—	-88.7%	-81.7%	-81.9%
ARQTArcutis Biotherapeutics, Inc.	$3.1B	+15.8%	-15.2%	+79.1%	—	+140.8%	-13.3%	+12.8%
KYMRKymera Therapeutics, Inc.	$6.8B	-1.4%	+14.0%	+71.4%	—	+230.0%	+64.1%	+149.4%
TERNTerns Pharmaceuticals, Inc.	$4.8B	+0.0%	+32.0%	+1191.5%	—	+339.4%	+204.0%	+187.9%
ACADACADIA Pharmaceuticals Inc.	$3.7B	-1.9%	-18.2%	-4.1%	—	-13.1%	-22.0%	-43.9%
INVAInnoviva, Inc.	$1.7B	-0.4%	+12.9%	+5.0%	—	+67.5%	+78.1%	+105.3%
PTGXProtagonist Therapeutics, Inc.	$7.1B	+6.1%	+25.9%	+98.4%	—	+278.8%	+177.0%	+838.4%
NUVLNuvalent, Inc.	$9.1B	+18.1%	+22.4%	+60.5%	—	+183.8%	+558.4%	+558.4%
RXRXRecursion Pharmaceuticals, Inc.	$1.4B	-3.4%	-25.0%	-41.7%	—	-68.0%	-89.9%	-82.5%

Compare:CTNM vs IMVT CTNM vs PRTA CTNM vs ARQT CTNM vs IMVT vs PRTA

About CTNM Dividend Returns

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of CTNM over the past year?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) delivered a return of 159.52% over the past year. Since CTNM does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in CTNM be worth today?

A $10,000 investment in Contineum Therapeutics, Inc. Class A Common Stock one year ago would be worth $25,952 today, representing a gain of $15,952.

Q3Does CTNM pay dividends?

Q4Did CTNM beat the S&P 500?

Yes, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) outperformed the S&P 500 by 136.84 percentage points over the past year. CTNM delivered a total return of 159.52%, compared to the S&P 500's 22.68%. This 136.84pp alpha means investors in CTNM earned more than a passive S&P 500 index fund.

Q5What is CTNM's worst drawdown?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) experienced a maximum drawdown of -29.84% over the past year, declining from its peak on 2025-12-11 to its trough on 2026-01-08. The stock recovered to its prior peak by 2026-01-27. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is CTNM's long-term total return over 10, 20, or 30 years?

Here are Contineum Therapeutics, Inc. Class A Common Stock (CTNM)'s long-term returns with dividends reinvested. Over 10 years, the total return is -23.0% (-2.6% CAGR) — $10,000 would have grown to $7,701. Over 20 years: -23.0% total return (-1.3% CAGR) — $10,000 → $7,701. Over 30 years: -23.0% total return (-0.9% CAGR) — $10,000 → $7,701. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was CTNM's best and worst year?

Contineum Therapeutics, Inc. Class A Common Stock's best calendar year was 2024 with a total return of -4.9%. Its worst year was 2025 with a total return of -21.1%. This range shows the volatility investors should expect — the difference between the best and worst year is 16.2 percentage points.

How much would $100/month in CTNM be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →